Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in MDS and AML patients: Phase Ib results.
暂无分享,去创建一个
P. Vyas | C. Takimoto | S. Kambhampati | N. Daver | G. Marcucci | J. Volkmer | M. Chao | A. Asch | R. Maute | D. Sallman | R. Komrokji | W. Donnellan | T. Bradley | M. A. Malki | D. Jeyakumar | Ming Lin | D. Lee | Joanna Van Elk